Bestellen Sie jetzt auf  www.cansativa.de

Cansativa Group schließt Finanzierungsrunde über 13 Millionen Euro ab.

16.2.2022 | Frankfurt / Mörfelden | cansativa
hero
hero
Zurück zur Übersicht

Frankfurt am Main, Germany, February 16, 2022

The largest medical cannabis distributor in Germany readies for expansion into the recreational market

Cansativa Group announced today it has closed a $15M Series B investment. The funding round was led by Casa Verde with participation by Argonautic Ventures and Munich-based family office Alluti. This represents Casa Verde’s largest investment in Germany and in Europe to date.

As one of Germany’s largest cannabis businesses, Cansativa is building the ‘Amazon’ of cannabis for Europe, offering its customers a B2B platform to manage every stage of the value chain from importing goods to distributing them to thousands of pharmacies across the country.

Given its exclusive relationship with German regulator, the Federal Institute for Drugs and Medical Devices (BfArM), Cansativa is the only company permitted to distribute domestically-grown medical cannabis.

The company will use the funding to expand its medical cannabis product portfolio and build out its recreational platform ahead of legalization in Germany.

“This investment from Casa Verde, one of the industry’s preeminent cannabis venture firms, is a significant milestone for our company and sends a strong message to the European cannabis market,” says Benedikt Sons, Founder, Managing Director and CEO of Cansativa Group. “It will allow us to realize our ambitious vision to become the operating backbone for cannabis retail in Germany and to play a vital role in enabling simple and safe access to cannabis for everyone.”

“Cansativa is strategically positioned to become one of the leading cannabis platforms in Europe,” says Yoni Meyer. “The company combines crucial industry expertise with an ambitious vision and a rapidly growing success story. We firmly believe this team will play a central role in the expected legalization in Germany and have a decisive impact on the European market, projected to reach $3.6B by 2025."

"Our goal is to simplify cannabis commerce in the rapidly-growing and evolving European environment. By ensuring product availability and offering flexible ancillary solutions, the Cansativa platform will soon be Europe's one-stop-shop for all things cannabis,” says Jakob Sons, Founder and Managing Director of Cansativa Group.

About Cansativa Group

Cansativa Group is Germany’s largest medical cannabis distributor, one of the country’s largest cannabis businesses and a driving force within Germany’s rapidly evolving cannabis industry. The company’s B2B platform manages every stage of the cannabis value chain from import, to distribution and related logistics, serving thousands of pharmacies across the country. Through an exclusive agreement with Germany’s regulatory body, Cansativa is the only company permitted to distribute domestically-grown medical cannabis.

www.cansativa-group.de

About Casa Verde

Casa Verde is the leading venture capital firm focusing on the cannabis industry. As both the domestic and international cannabis markets continue to evolve and mature, Casa Verde maintains a view that the cannabis industry will be among the most compelling investment themes of our generation.

www.casaverdecapital.com

For further information contact:

US PR for Cansativa

Ellyn Winters-Robinson / Ignition Communications

ellyn@ignition.ca / +1 519 574 2196

German PR

Ioana Freise pr@cansativa.de

www.cansativa-group.de

Cansativa GmbH, Hessenring 15i, 64546 Mörfelden-Walldorf

Zurück zur Übersicht
15.12.2022 | Frankfurt / Mörfelden

AMICI takes the next step – leading the premium medical cannabis market with new THC levels.

After launching a new premium medical cannabis brand under the name “AMICI” in Mid-November, Cansativa Group, Germany’s leading cannabis platform, now closes the year of 2022 with a new high THC product, which sets itself at the top of the medical cannabis market. The previously launched product line consists of the two types “Strawberry Banana” and “Cherry Pie” and features high microbiological purity beside particular product details, which have been tested by experts and patients in the last weeks.
30.11.2022 | Frankfurt / Mörfelden

Die G-BA Änderungen der Arzneimittel-Richtlinien führen zu großen Risiken..

Ausgangslage: Die Handhabe von Cannabis als Medizin steht auf dem Prüfstand. Seit dem Inkrafttreten des „Gesetzes zur Änderung betäubungsmittelrechtlicher und anderer Vorschriften“ im März 2017 dürfen Cannabisarzneimitteln als Therapiealternative verordnet werden. Seit dem Inkrafttreten des „Gesetzes zur Änderung betäubungsmittelrechtlicher und anderer Vorschriften“ im März 2017 dürfen Cannabisarzneimitteln als Therapiealternative verordnet werden. Die Verantwortung hierfür wurde im selben Jahr in die Hände der behandelnden Ärzt:innen gelegt. Die Kosten, die für Patient:innen im Rahmen der Behandlung entstehen, wurden hierbei –bei vorheriger Kostenübernahmegenehmigung –durch die gesetzliche Krankenversicherung übernommen.
9.11.2022 | Frankfurt / Mörfelden

AMICI - Premium medical cannabis enabled by Cansativa

The Cansativa Group, Germany's leading cannabis platform, is launching a new premium medical cannabis brand under the name "AMICI". This new product line consists of the two products, „Strawberry Banana" and "Cherry Pie", which have a high microbiological purity. All products ofthe brand "AMICI" are unirradiated. The cultivars derive from strictly EU-GMP controlled indoorcultivation facilities with many years of experience. The addition of "AMICI" to the productportfolio is another milestone and important step for Cansativa.